Business
Natco Pharma plant in Visakhapatnam gets VAI status from US drug regulator
Reported by Abhishek Tiwari (Copy Editor) · The Hindu - Business ·
Natco Pharma has received an inspection report from the United States Food and Drug Administration for its medicine manufacturing unit in Visakhapatnam.
Inspection Details
The plant makes finished dosage formulations and is located in the Parawada area of Visakhapatnam. The US drug regulator inspected this facility between August 17 and August 21. During this visit, the regulator issued Form-483 with four observations.
Regulatory Classification
The company stated in a stock exchange filing that the plant received a voluntary action indicated classification. This status means the regulator found some objectionable conditions or practices during the check. However, the agency is not ready to take or suggest any administrative or legal action against the company right now.
Context
Drug regulators routinely inspect pharmaceutical manufacturing facilities to ensure they meet required safety and quality standards. The voluntary action indicated classification is a middle-tier outcome that points out areas needing improvement without triggering penalties.
More in Business
Business• UpdatedExplainerSource: The HinduImportant
SEBI proposes scrapping strict FPI rules to boost foreign investment
Reported by Faizan Khan (Staff Writer) · The Hindu - Business ·
BusinessSource: The HinduImportant
SEBI Proposes Relaxing Strict Disclosure Rules for Foreign Investors
Reported by Ishita Mukherjee (Staff Writer) · The Hindu - Business ·

BusinessSource: The HinduImportant
Tiruppur Exporters Urged to Focus on Financial Discipline as New Trade Pacts Open Global Markets.
Reported by Arjun Sethi (Fact-Checker) · The Hindu - Business ·
